-+ 0.00%
-+ 0.00%
-+ 0.00%

Candel Therapeutics To Hold Conference Call On May 15 To Discuss Extended Follow-Up Data From Its Phase 3 Clinical Study Of Aglatimagene Besadenovec In Participants With Intermediate- To High-Risk Localized Prostate Cancer

Benzinga·05/04/2026 12:17:41
Listen to the news

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced that Candel's management will host a webcast and conference call on Friday, May 15, 2026 at 1:00 PM ET. The call will discuss the Company's extended follow-up data from the phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with intermediate- to high-risk localized prostate cancer. The discussion will follow the oral plenary presentation of these data by Mark G. Garzatto, M.D., Professor of Urology at Oregon Health & Science University and the Portland VA Medical Center, at the American Urological Association (AUA) 2026 Annual Meeting.